Immunotherapy最新文献_第3页

Drug evaluation: mepolizumab in chronic obstructive pulmonary disease. 药物评价：mepolizumab治疗慢性阻塞性肺疾病。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-04-01 Epub Date: 2025-05-14 DOI: 10.1080/1750743X.2025.2504326

Matheus Rabahi, Ian D Pavord

{"title":"Drug evaluation: mepolizumab in chronic obstructive pulmonary disease.","authors":"Matheus Rabahi, Ian D Pavord","doi":"10.1080/1750743X.2025.2504326","DOIUrl":"10.1080/1750743X.2025.2504326","url":null,"abstract":"Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality globally, marked by persistent respiratory symptoms and exacerbations. It is now acknowledged to be a heterogeneous disease with respect to clinical expression and key driving mechanisms. Standard therapies, including bronchodilators and corticosteroids, often fail to adequately control symptoms and exacerbations in patients and there is an important unmet need for new treatments. There has been encouraging progress with biological treatments for patients with COPD and type-2 airway inflammation, a phenotype found in approximately 40% of COPD cases. The first of these, Mepolizumab, is a monoclonal antibody targeting interleukin-5 (IL-5), and thereby reducing blood and tissue eosinophil numbers. Here we review the initial clinical trial data with mepolizumab in type-2 high COPD. We suggest that the modest efficacy seen in patients with severe disease may not be reflective of the impact of treatment in patients with active type-2 inflammation and less associated lung and extra-pulmonary damage. We suggest that the way forward is to assess whether clinically important modification of disease course occurs with treatment in patients with high disease activity and low associated damage.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"399-408"},"PeriodicalIF":2.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12091904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data. 大麻素对免疫检查点抑制剂反应的影响：CCTG对个体患者数据的汇总分析。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-03-01 Epub Date: 2025-04-04 DOI: 10.1080/1750743X.2025.2485012

Courtney H Coschi, Keyue Ding, Justin Tong, Dongsheng Tu, Christopher O'Callaghan, Natasha B Leighl, Francisco Vera-Badillo, Rosalyn A Juergens, Desiree Hao, Lesley Seymour, Daniel J Renouf, Eric Chen, Pierre-Olivier Gaudreau, Andrea S Fung

{"title":"Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data.","authors":"Courtney H Coschi, Keyue Ding, Justin Tong, Dongsheng Tu, Christopher O'Callaghan, Natasha B Leighl, Francisco Vera-Badillo, Rosalyn A Juergens, Desiree Hao, Lesley Seymour, Daniel J Renouf, Eric Chen, Pierre-Olivier Gaudreau, Andrea S Fung","doi":"10.1080/1750743X.2025.2485012","DOIUrl":"10.1080/1750743X.2025.2485012","url":null,"abstract":"Background: Immune checkpoint inhibitors (ICIs) benefit patients across various tumor types. ICIs block cancer and T-cell interactions whereas cannabinoids may inhibit T-cell activation, reducing lysis of tumor cells. Interactions between cannabinoid use and dual ICI treatment remain unknown.Methods: Individual patient data from 4 Canadian Cancer Trials Group (CCTG) trials of patients treated with dual ICI ± chemotherapy (n = 684) were pooled. Cochran - Mantel - Haenszel and log-rank tests (stratified by trial/treatment arms) correlated cannabinoid use with clinicopathologic characteristics, Best Overall Response (BOR)/iBOR per RECIST 1.1/iRECIST, Progression-Free Survival (PFS)/iPFS, Overall Survival (OS) and immune-related adverse events (irAEs).Results: Sixty-five (9.5%) patients took cannabinoids at any time on trial, 32 (4.7%) of which were using cannabinoids at baseline. By multivariate analysis, cannabinoid use at baseline was significantly associated with improved iPFS (0.05), but not iBOR (p = 0.15), PFS (p = 0.12), OS (p = 0.35) or incidence of grade 1/2 or 3/4 irAEs (p = 0.96 and 0.65 respectively). Results were not significantly different with cannabinoid use at any time on trial.Conclusion: Improved iPFS with cannabinoid use in patients treated with durvalumab plus tremelimumab ± chemotherapy did not translate into OS benefits. This study supports the safe use of cannabinoids in the context of combination ICI therapy.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"257-268"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12036482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143784464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A plain language summary of a review about omalizumab for people with chronic spontaneous urticaria. 一篇关于奥玛珠单抗治疗慢性自发性荨麻疹的综述。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-03-01 Epub Date: 2025-04-07 DOI: 10.1080/1750743X.2025.2484921

Thomas B Casale, Ana Maria Gimenez-Arnau, Jonathan A Bernstein, Michael Holden, Torsten Zuberbier, Marcus Maurer

引用次数: 0

Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management. 与免疫检查点抑制剂治疗相关的胃肠道毒性：风险和管理。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-03-01 Epub Date: 2025-03-07 DOI: 10.1080/1750743X.2025.2473305

Carolina Colli Cruz, Maria Julia Moura Nascimento Santos, Sharada Wali, Krishnavathana Varatharajalu, Anusha Thomas, Yinghong Wang

引用次数: 0

Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis. 营养状况与癌症免疫治疗的PFS和OS: MOUSEION-010荟萃分析

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-03-01 Epub Date: 2025-03-25 DOI: 10.1080/1750743X.2025.2483656

Elsa Vitale, Lorenza Maistrello, Alessandro Rizzo, Oronzo Brunetti, Raffaella Massafra, Veronica Mollica, Francesco Massari, Matteo Santoni

{"title":"Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis.","authors":"Elsa Vitale, Lorenza Maistrello, Alessandro Rizzo, Oronzo Brunetti, Raffaella Massafra, Veronica Mollica, Francesco Massari, Matteo Santoni","doi":"10.1080/1750743X.2025.2483656","DOIUrl":"10.1080/1750743X.2025.2483656","url":null,"abstract":"Background: The MOUSEION-010 Meta-Analysis assessed the association between nutritional status and clinical outcomes such as Progression Free Survival (PFS) and Overall Survival (OS) among cancer patients treated with immune checkpoint inhibitors (ICIs).Methods: Nutritional status was assessed based on the Prognostic Nutrition Index (PNI), Geriatric Nutritional Risk Index (GNRI) and Controlling Nutritional Status (CONUT) indexes. Databases consulted were: Embase, PubMed, Scopus and Web of Science.Results: PNI and GNRI indexes did not show a significant association with both PFS and OS, while CONUT index displayed a significant difference in PFS between the two groups, in favor of the control group (Z = 4.04; p < 0.01) also without any publication bias (β= -1.27; 95% CI = [-2.13; -0.42]; p = 0.10]). The same trend was recorded in OS, too (Z = 4.24; p < 0.01). However, publication bias was present (β = 1.89; 95% CI = [1.26; 2.54]; p = 0.028]) and the numerosity of the studies did not reveal the sufficient statistical power to obtain reliable results.Conclusion: Malnutrition could negatively impact cancer patients, especially in advanced phases. Our findings could be associated with the reduction of physical ability and daily activity performance, lower compliance with treatment protocols, and shorter survival outcomes.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"269-281"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12013447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is it time to revisit the significance of PD-L1 expression in assisting our treatment decisions? 是时候重新审视PD-L1表达在帮助我们的治疗决策中的意义了吗？

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-03-01 Epub Date: 2025-03-21 DOI: 10.1080/1750743X.2025.2483152

Georgios I Papageorgiou, Nikolaos Skouteris, Maria Grenzelia, Emmanouil Maragkoudakis, Kleopatra Eleftheriou

引用次数: 0

Incidence and impact of immune combination therapies adverse events in advanced renal cell carcinoma patients. 晚期肾细胞癌患者免疫联合治疗不良事件的发生率及影响。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-03-01 Epub Date: 2025-03-28 DOI: 10.1080/1750743X.2025.2482510

Martina Catalano, Giulia Venturi, Alessia Salfi, Francesco Bloise, Federico Paolieri, Luca Galli, Michele Sisani, Laura Doni, Giandomenico Roviello

{"title":"Incidence and impact of immune combination therapies adverse events in advanced renal cell carcinoma patients.","authors":"Martina Catalano, Giulia Venturi, Alessia Salfi, Francesco Bloise, Federico Paolieri, Luca Galli, Michele Sisani, Laura Doni, Giandomenico Roviello","doi":"10.1080/1750743X.2025.2482510","DOIUrl":"10.1080/1750743X.2025.2482510","url":null,"abstract":"Background: Immune (IO)-combination therapies have revolutionized the treatment of advanced renal cell carcinoma (aRCC) but are more frequently associated with adverse events (AEs) compared to tyrosine kinase inhibitors (TKI) alone. This retrospective study aimed to evaluate the incidence and prognostic significance of AEs in patients receiving combination therapies.Methods: We included patients treated with nivolumab/ipilimumab (NI), nivolumab/cabozantinib (NC), or pembrolizumab/axitinib (PA) at four Italian oncology centers between November 2023 and June 2024. The impact of AEs on progression-free survival (PFS), overall survival (OS), overall response, and disease control rate were analyzed using descriptive statistics, Kaplan-Meier method, and Cox regression.Results: AEs occurred in 78.8% of NI, 87.9% of NC, and 92.3% of PA patients. Grade 3-4 AEs were more common in IO-TKI vs. IO-IO combinations (32.9% vs. 15.1%, p = 0.05). Pruritus and pulmonary events were more frequent with IO-IO, while hypertension and mucositis were more common with IO-TKI. High-grade AEs did not impact PFS or OS, but TKI reduction due to AEs was associated with longer OS (p < 0.01). Steroid use also improved OS (p = 0.04).Conclusion: AEs are common in ICI-based therapies for RCC. While they do not negatively affect survival, their management, especially through dose reductions or steroids, may improve outcomes.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"247-256"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12013433/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Benralizumab for the treatment of chronic spontaneous urticaria: a plain language summary of the ARROYO study. 本拉珠单抗治疗慢性自发性荨麻疹：ARROYO 研究的简明摘要。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-03-01 Epub Date: 2025-03-30 DOI: 10.1080/1750743X.2025.2480052

Sabine Altrichter, Ana Maria Giménez-Arnau, Jonathan A Bernstein, Martin Metz, Maria Bergquist, Laura Brooks, Calvin N Ho, Priya Jain, Pradeep B Lukka, Eva Rodriguez-Suárez, Claire Walton, Lila Bahadori

引用次数: 0

Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma. 优化TIL治疗葡萄膜黑色素瘤：从皮肤黑色素瘤中吸取的教训和未吸取的教训。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-03-01 Epub Date: 2025-03-18 DOI: 10.1080/1750743X.2025.2478808

Shravan Leonard-Murali, Udai S Kammula

{"title":"Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma.","authors":"Shravan Leonard-Murali, Udai S Kammula","doi":"10.1080/1750743X.2025.2478808","DOIUrl":"10.1080/1750743X.2025.2478808","url":null,"abstract":"Adoptive transfer of tumor infiltrating lymphocytes (TIL-ACT) is a personalized cancer therapy that harnesses the anti-tumor activity of tumor resident T cells through ex vivo activation and expansion. This therapy involves the infusion of a single dose of ex vivo expanded TIL together with high dose IL-2 following a preparative lymphodepleting chemotherapy. The United States Food and Drug Administration approved lifileucel in 2024 as the first autologous TIL product for patients with advanced cutaneous melanoma (CM), adding to the list of approved immunotherapies for this highly immunogenic cancer. However, the role for TIL-ACT in other solid tumors is unclear, especially for poorly immunogenic cancers with low tumor mutational burden. In this review, we describe the historical development of TIL-ACT, summarize the clinical results in advanced CM, and describe the novel application of TIL-ACT to metastatic uveal melanoma (UM), a prototypic immunotherapy-resistant solid tumor. We will highlight key biologic differences between CM and UM, their consequential influence on the manufacturing of UM-specific TIL products, and the development of novel biomarkers for precision TIL-ACT for metastatic UM.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"283-291"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12013418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Absence of pre-transplant T cell response against LAA is associated with Flt3-ITD mutation and increased relapse-risk in AML patients with HSCT. 移植前T细胞缺乏对LAA的反应与Flt3-ITD突变和AML合并HSCT患者复发风险增加有关。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-03-18 DOI: 10.1080/1750743X.2025.2478804

Markéta Šťastná-Marková, Petr Hainz, Jitka Kryštofová, Jana Macková, Kateřina Roubalová, Jan Vydra, Šárka Němečková

{"title":"Absence of pre-transplant T cell response against LAA is associated with Flt3-ITD mutation and increased relapse-risk in AML patients with HSCT.","authors":"Markéta Šťastná-Marková, Petr Hainz, Jitka Kryštofová, Jana Macková, Kateřina Roubalová, Jan Vydra, Šárka Němečková","doi":"10.1080/1750743X.2025.2478804","DOIUrl":"10.1080/1750743X.2025.2478804","url":null,"abstract":"Aims: This study aimed to examine changes in the repertoire of functional T-cells specific for six leukemia-associated antigens (LAA), including WT1, PRAME, MUC1, CCNA1, NPM1, and NPM1c, during immune reconstitution following allogeneic transplantation of hematopoietic stem cells (HSCT) in patients with acute myeloid leukemia.Patients & methods: LAA-specific T cell response was measured by ELISPOT- IFNγ and intracellular cytokine staining in 47 patients before starting conditioning therapy (baseline) and 7 months after HSCT.Results: The positive cumulative LAA-specific T cell response before HSCT was associated with a decreased risk of relapse after HSCT. The prevalent genetic aberration - an internal tandem duplication of Fms 3 - related receptor tyrosine kinase, which has been previously implicated in immune escape mechanisms, is presented here for the first time as a factor associated with the absence of an adaptive T cell response against multiple LAAs. T-cell specific responses against wild-type and mutated NPM1 antigens were less frequent in the study cohort and did not correlate with mutations in the NPM1 gene.Conclusions: Our results showed that the T-cell response to LAA can be reconstituted after HSCT. Measurement of functional pre-transplant T-cell responses against multiple LAAs could help to find patients with an increased risk of relapse.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"185-190"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0